Placebo News and Research

RSS

WHO resumes hydroxychloroquine drug trial in COVID-19

The coronavirus disease (COVID-19) has rippled across the world with a devastating effect. As scientists raced to find an effective treatment for patients, existing malaria and rheumatoid arthritis drug hydroxychloroquine became one of the most popular candidates.

5 Jun 2020

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Netakimab is a humanized anti-interleukin 17A antibody approved for the treatment of moderate-to-severe plaque psoriasis.

5 Jun 2020

Assessing the integrity of remdesivir clinical trial during COVID-19 pandemic

As acknowledged in the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19 recently published in Lancet (Wang, et al., April 29, 2020), a statistician at Rutgers Cancer Institute of New Jersey was called on to guard the integrity of that trial.

4 Jun 2020

DFG to establish ten new Collaborative Research Centers

The Deutsche Forschungsgemeinschaft is establishing ten new Collaborative Research Centres to further support top-level research in German universities.

4 Jun 2020

Hydroxychloroquine not able to prevent development of COVID-19, UMN trial shows

Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

4 Jun 2020

Original Hamilton Rating Scale for Depression was unstructured, indicates study

The format of the original Hamilton Rating Scale for Depression (HAM-D) was unstructured: only general instructions were provided for rating individual items.

4 Jun 2020

Pre-clinical data for Celltrion’s antiviral antibody treatment shows 100-fold reduction in viral load of SARS-CoV-2

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.

4 Jun 2020

Mandibular advancement device helps relieve daytime sleepiness in patients with sleep apnea

With the help of a mandibular advancement device, daytime sleepiness of patients with obstructive sleep apnoea can be relieved.

3 Jun 2020

Octapharma extends support for COVID-19 study following promising preliminary data

Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic, those experiencing hypoxia and who are at the highest risk of requiring mechanical ventilation.

3 Jun 2020

Anesthetic drug Ketamine uses serotonin receptors to relieve depression

Ketamine is a drug used to induce general anesthesia. It has also been found to act rapidly to relieve depression that has failed to respond to two other rounds of medication. A new study published in the journal Translational Psychiatry in May 2020 reports the mechanism of action of the drug, which was hitherto unknown. This could help find new ways to treat this debilitating and sometimes fatal condition.

31 May 2020

Researchers show how ketamine fights difficult-to-treat depression

The anaesthetic drug ketamine has been shown, in low doses, to have a rapid effect on difficult-to-treat depression.

31 May 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.

29 May 2020

Chronobiological treatment can help treat insomnia

Insomnia disorder is the second-most common mental health problem and a major risk factor for depression. Cognitive behavioral therapy for insomnia (CBTi) is the treatment of choice and has successfully been provided through the Internet (ICBTI).

29 May 2020

Targeted therapy shows immense benefit for patients with early stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

29 May 2020

5-day Remdesivir dose works as well as the 10-day dose in COVID-19, study finds

With more than 5.8 million people infected with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the search is on for an effective SARS-CoV-2 vaccine or drug to treat COVID-19 disease.

28 May 2020

CBD treatment improves arthritis symptoms in dogs, study finds

A team led by researchers at Baylor College of Medicine in collaboration with Medterra CBD conducted the first scientific studies to assess the potential therapeutic effects of cannabidiol for arthritic pain in dogs, and the results could lead the way to studying its effect in humans.

28 May 2020